Medicaments for treating erectile disorders

Patent 5190967 Issued on March 2, 1993. Estimated Expiration Date:

June 4, 2011. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

2-(4,5-Dihydro-1H-imidazol-2-yl)-2,3-dihydroindole derivatives and their application as ଱₂ receptor antagonist or ଱₁ receptor agonists
Patent #: 4659731
Issued on: 04/21/1987
Inventor: Bigg , et al.

଱₂ -blocking derivatives of imidazole
Patent #: 4738979
Issued on: 04/19/1988
Inventor: Calderon , et al.

Sulfonyl-decahydro-8H-isoquino[2,1-G][1,6]-naphthyridines and related compounds useful as ଱₂ -blockers
Patent #: 4791108
Issued on: 12/13/1988
Inventor: Clark

Optical isomers of sulfonyldecahydro-8H-isoquino-(2,1-G)(1,6) naphthyridines and related compounds useful as ଱₂ -blockers
Patent #: 4886798
Issued on: 12/12/1989
Inventor: Clark

Decahydro-8H-isoquino(2,1-g)(1,6)naphthyridine derivatives and related compounds
Patent #: 4956365
Issued on: 09/11/1990
Inventor: Clark, et al.

Process for the preparation of decahydro-8H-isoquino[2,1-g][1,6]naphthyridine derivatives Patent #: 4960891
Issued on: 10/02/1990
Inventor: Clark

Inventor

Riley, Alan J.

Assignee

Glaxo Group Limited

Application

No. 711068 filed on 06/04/1991

US Classes:

514/411Tricyclo ring system having the five-membered hetero ring as one of the cyclos

Examiners

Primary: Schenkman, Leonard

Attorney, Agent or Firm

Bacon & Thomas

Foreign Patent References

0439320A1 EP. 07/13/1991

International Class

A61K 031/40

Foreign Application Priority Data

1990-06-05 GB

Abstract

The use of a compound of formula I ##STR1## wherein R is a hydrogen atom or a group selected from C1-6 alkyl (optionally substituted by C3-7 cycloalkyl), C3-6 alkenyl, C3-6 alkynyl, C3-7 cycloalkyl, aralkyl (in which the alkyl moiety contains 1-5 carbon atoms) and --CHO;R1 and R2, which may be the same or different, represent a hydrogen atom, a halogen atom or a group selected from C1-4 alkyl, C1-4 alkoxy, hydroxyl, cyano, nitro and --NR3 R4 where R3 and R4 is each a hydrogen atom or a C1-4 alkyl group andX is an oxygen atom or a group --CH2- ; or a physiologically acceptable salt or hydrate thereof for treating, relieving or preventing the effects of sexual dysfunction.Preferred compounds include trans-5-fluoro-2,3,3a,9a-tetrahydro-1H-[1,4] benzodioxino [2,3-c]pyrrole and trans-5-fluoro-1,2,3,3a,9,9a-hexahydro[1] benzopyrano [2,3-c]pyrrole.Conditions that may be treated in this manner include, in the case of the male, erectile inadequacy and, in the case of the female, sexual arousal disorder.